Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DNX-2440 for Resectable Colorectal Liver Metastasis

ABSTRACT: The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery. Up to 18 patients will receive two sequential intra-tumoral injections of DNX-2440 into a metastatic liver tumor prior to surgery for liver resection, to evaluate safety and biological endpoints across 3 dose levels (dose escalation). Upon conclusion of the dose-escalation phase, the selected safe and biologically appropriate dose will be administered using the same schema for an additional 12 patients with colorectal cancer liver metastasis (expansion cohort) using established biologic endpoints.

DISEASE(S): Sarcoma,Melanoma,Colorectal Cancer,Liver Neoplasms,Breast Cancer,Periampullary Cancer,Neoplasm Metastasis,Liver Metastases,Neoplasms, Second Primary,Liver Metastasis Colon Cancer,Gastric Cancer,Squamous Cell Carcinoma,Carcinoma, Renal Cell,Renal Cell Cancer,Gastrointestinal Stromal Tumors

PROVIDER: 2364327 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A20 Role in Liver regeneration

2010-09-18 | GSE24203 | GEO

E-PROT-100

Project description:Biomarkers discovery for Colorectal cancer liver metastasis

2023-06-21 | E-PROT-100 | ExpressionAtlas

A20 Role in Liver regeneration

Project description:Genome wide transcriptional profiling on liver mRNA retrieved from recombinant adenovirus A20 (rAd.A20) and rAd.bgalactosidase transduced livers, before and 24 hours after 78% extended liver resection. Overexpression of the NF-kB inhibitory protein A20 improves recovery of liver function and mass following extended liver resection and severe liver ischemia reperfusion injury in mice. In this project, we explored effects of A20 using transcriptional profiling on liver mRNA retrieved from recombinant adenovirus A20 (rAd.A20) and rAd.bgalactosidase transduced livers, before and 24 hours after 78% extended liver resection. A20 or beta-galactosidase gene expression in the mouse liver was achieved by penile vein injection of 1x109 pfu of rAd. in 100uL of normal saline, which results in optimal transgene expression 5 days after injection in 30% to 40% of hepatocytes (Longo et al, 2005). Extended (78%) LR, consisting of resection of the lateral, medial, left, and right lobes, was performed 5 days following rAd. administration in 8-week old BALB/c mice weighing 25 to 30 grams (Taconic, Germantown, NY), as described (Longo et al, 2005). RNA was extracted from the resected portion of the liver (before samples) and from the remnant liver 24 hours after resection (after samples). RNA from three animals was pooled per microarray and 2 microarrays per group were performed.

2010-09-18 | E-GEOD-24203 | biostudies-arrayexpress

Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy

Project description:Although oncolytic adenoviruses have been widely studied for their direct oncolytic activity and immunomodulatory role in cancer immunotherapy, the immunosuppressive feedback loop induced by oncolytic adenoviruses remains poorly studied. Here, we showed that type V adenovirus (ADV) induces the polarization of tumor-associated macrophages (TAMs) to the M2 phenotype and increases the infiltration of regulatory T cells (Tregs) in the tumor microenvironment (TME). By selectively compensating for these deficiencies, Tα1 reprogrammed “M2-like” TAMs toward an antitumoral phenotype, thereby reprogramming the TME into a state more beneficial for antitumor immunity. Moreover, ADVTα1 was constructed by harnessing the merits of all the components for the aforementioned combinatorial therapy. Both in vitro and in vivo data showed that both exogenously supplied and adenovirus-produced Tα1 orchestrate TAM reprogramming and enhance the antitumor efficacy of ADV via CD8+ T cells, showing promising prospects for clinical translation. Our findings provide inspiration for improving oncolytic adenovirus combination therapy and designing new oncolytic engineered adenoviruses.

2024-07-04 | GSE271202 | GEO

Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy

2024-06-28 | GSE271046 | GEO

Gene expression profile, population of macrophages and lymphocytes of the spleen in conditions of liver regeneration after 70% resection in mice

Project description:The aim of our work was to study the expression profile of spleen genes during liver regeneration, to identify possible biologically active substances that affect reparative processes and inflammation in other organs, as well as the state of the monocytic-macrophage and lymphocytic population of the spleen after liver resection. We used microarrays for comparison of spleen gene expression on different time periods after 70% liver resection

2023-09-27 | GSE232531 | GEO

Transcription profiling of human DU-145, PC-3MM2 cell lines treated with irradiation reveals Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation

Project description:Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation

2009-05-13 | E-MEXP-2172 | biostudies-arrayexpress

Spatial transcriptome for investigating tumor microenvironment remodeling mediated by a chimeric oncolytic adenovirus combined with PD-1 antibody

Project description:We constructed a chimeric oncolytic adenovirus which is a novel broad-spectrum anticancer product with multiple mechanisms of synergistic and potentiated immunotherapy

2024-08-28 | GSE185610 | GEO

Single-Cell Transcriptome Sequencing for investigating tumor microenvironment remodeling mediated by a chimeric oncolytic adenovirus combined with PD-1 antibody

Project description:We constructed a chimeric oncolytic adenovirus which is a novel broad-spectrum anticancer product with multiple mechanisms of synergistic and potentiated immunotherapy

2024-08-28 | GSE185575 | GEO

Paclitaxel resistance in ovarian cancer increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control

Project description:The microtubule-stabilising drug paclitaxel has activity in relapsed ovarian cancer. However, resistance frequently develops. Oncolytic adenoviruses are a novel cancer therapy, and replicate selectively within and lyse malignant cells, leading to productive infection of neighbouring cells. We found increased efficacy of adenoviruses of multiple subtypes in paclitaxel-resistant ovarian cancer cells. There was increased expression of a key adenovirus receptor, CAR (coxsackie adenovirus receptor), due to increased transcription that resulted from histone modification. Moreover, CAR transcription increased in intraperitoneal xenografts with acquired paclitaxel resistance and in tumours from patients with paclitaxel-resistant ovarian cancer. Finally, we identified dysregulated cell cycle control as a second mechanism of increased adenovirus efficacy in paclitaxel-resistant ovarian cancer and that inhibition of CDK4/6 using PD-0332991 was able both to reverse paclitaxel resistance and reduce adenovirus efficacy. Thus, paclitaxel resistance increases oncolytic adenovirus efficacy via at least two separate mechanisms. Parental SKOV3 and paclitaxel-resistant SKOV3-TR cells were analysed in duplicate

2015-12-10 | E-GEOD-54772 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data